Evidence map›Paper›PMID 40252138›Full record

SynthesisArchives of dermatological research2025

Safety and efficacy of Simvastatin in the treatment of vitiligo: a systematic review and meta-analysis of randomized controlled trials.

Song Zhang, Ibrahim Serag, Shereen Mohamed Olama, Mahmoud G A Saleh, E A Shaban, Mostafa Hossam El Din Moawad

Abstract readSystematic ReviewMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Song ZhangJinan City People's Hospital, Jinan People's Hospital Affiliated to Shandong First Medical University, Jinan, China.
Ibrahim SeragFaculty of Medicine, Mansoura University, Mansoura, Egypt. Hemaserag89@gmail.com.
Shereen Mohamed OlamaDepartment of Internal Medicine, College of Medicine, Northern Border University, Arar, Saudi Arabia.
Mahmoud G A SalehDepartment of Chemistry, College of Science, Northern Border University, Arar, Saudi Arabia.
E A ShabanFaculty of Medicine, Zagazig University, Zagazig, Egypt.
Mostafa Hossam El Din MoawadAlexandria Main University Hospital, Alexandria, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vitiligo is an autoimmune skin disorder characterized by progressive depigmentation due to melanocyte destruction. Despite various treatment options, achieving complete repigmentation remains challenging. Simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has demonstrated anti-inflammatory and immunomodulatory effects, making it a promising candidate for vitiligo treatment. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of Simvastatin in vitiligo treatment. A systematic search of PubMed, Scopus, Web of Science, and Cochrane Library was conducted following PRISMA guidelines. Only RCTs comparing Simvastatin with a control or pre-post Simvastatin assessments in vitiligo patients were included. Six RCTs with a total of 371 patients met the eligibility criteria. The primary outcomes analyzed were VASI reduction and excellent repigmentation response (≥ 75% repigmentation). Secondary outcomes included changes in total cholesterol, triglycerides, and low-density lipoprotein (LDL) levels. Meta-analyses were performed using a random-effects model, and heterogeneity was assessed using the I

Indexed as

Hydroxymethylglutaryl-CoA Reductase InhibitorsSimvastatinVitiligoHumansRandomized Controlled Trials as TopicSkin PigmentationTreatment OutcomeHydroxymethylglutaryl-CoA Reductase InhibitorsSimvastatinLipid profileMeta-analysisRepigmentationSimvastatinStatinsVASIVitiligo

Identifiers

PMID40252138

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.